Provided by Tiger Trade Technology Pte. Ltd.

Corbus Pharmaceuticals

8.86
-1.7350-16.38%
Pre-market: 9.020.1567+1.77%06:11 EDT
Volume:1.00M
Turnover:9.41M
Market Cap:171.36M
PE:-1.46
High:10.72
Open:10.60
Low:8.85
Close:10.60
52wk High:20.56
52wk Low:7.12
Shares:19.34M
Float Shares:17.42M
Volume Ratio:1.58
T/O Rate:5.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0889
EPS(LYR):-5.9000
ROE:-95.58%
ROA:-53.00%
PB:1.68
PE(LYR):-1.50

Loading ...

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
May 28

Wedbush Sticks to Their Buy Rating for Corbus Pharmaceuticals (CRBP)

TIPRANKS
·
May 27

Corbus Pharmaceuticals Holdings Inc : Wedbush Cuts Target Price to $30 From $38

THOMSON REUTERS
·
May 27

Corbus Pharmaceuticals Holdings Inc. Stock Slides 30.3%, Underperforms Peers

Dow Jones
·
May 27

Corbus Pharmaceuticals Falls on Reports of Adverse Events in Tumor-Treatment Study

Dow Jones
·
May 27

Corbus Pharmaceuticals share selloff overdone, says Guggenheim

TIPRANKS
·
May 27

Analysts Are Bullish on These Healthcare Stocks: LifeMD (LFMD), Corbus Pharmaceuticals (CRBP)

TIPRANKS
·
May 27

Corbus Pharmaceuticals Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
May 27

Corbus reports 42.9% response rate for CRB-701 in Phase 1/2 second-line oropharyngeal cancer study

Reuters
·
May 26

Corbus Pharmaceuticals Reports Updated Crb-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

THOMSON REUTERS
·
May 26

Corbus Pharmaceuticals Holdings Inc - Crb-701 Generally Safe and Well Tolerated With Discontinuation Rates Below 3%

THOMSON REUTERS
·
May 26

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

GlobeNewswire
·
May 26

U.S. RESEARCH ROUNDUP-Apollo, Phillips 66, Valero Energy

Reuters
·
May 26

Corbus Pharmaceuticals Is Maintained at Outperform by Mizuho

Dow Jones
·
May 22

Mizuho Adjusts Price Target on Corbus Pharmaceuticals to $44 From $40, Maintains Outperform Rating

MT Newswires Live
·
May 22

U.S. RESEARCH ROUNDUP-Jazz Pharmaceuticals, Target, Workday

Reuters
·
May 22

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
May 22

Corbus Pharma director Brent Pfeiffenberger files initial beneficial ownership statement

Reuters
·
May 22

Corbus Pharmaceuticals Appoints First Chief Business Officer

TIPRANKS
·
May 21

Corbus Pharma names Nishant Saxena chief business officer

Reuters
·
May 21